Data completeness
3/8 — Basic
MYCELEX-G (clotrimazole) by R-Pharm US is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and malassezia furfur . Approved for candidiasis, hiv infections, otomycosis and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYCELEX-G (clotrimazole) is a broad-spectrum antifungal agent administered as a vaginal tablet that treats candidiasis and other fungal infections. The drug works by disrupting fungal cell membranes, causing leakage of intracellular phosphorus compounds and nucleic acid breakdown, demonstrating both fungistatic and fungicidal activity. It is minimally absorbed when applied topically or vaginally, with concentrations declining from the stratum corneum to subcutaneous tissue.
Pre-Launch
As a pre-launch product, MYCELEX-G represents a build-phase opportunity with anticipated team expansion in commercial, medical affairs, and regulatory roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and Malassezia furfur . The primary action of clotrimzole is against dividing and growing organisms. In vitro ,…
Worked on MYCELEX-G at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.